Amlenetug

Phase 3Small molecule

Lundbeck

Amlenetug is one of 14 small molecule programs targeting Multiple System Atrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple System AtrophyActive, not recruiting

Multiple System AtrophyPhase 3

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Northera

Rifadin

Sudafed

Rilutek

AAzurity Pharmaceuticals

Lu AF95245

1 6

Amlenetug

Lundbeck

Phase 3

1 7

TEV-56286

Teva

Phase 2

2 8

Foralumab

TTiziana Life Sciences LTD

Phase 2

1 9

Bendopa

MMerz North America, Inc.

Preclinical

1 10

ATH434

AAlterity Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Active, not recruiting

Multiple System Atrophy

NCT06706622

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

Interventional, Randomized, Double-blind, Placebo-controlled, Optional Open-label Extension Trial of Lu AF82422 in Participants With Multiple System Atrophy

Active, not recruiting· Lundbeck logo

Lundbeck·Phase 3·NCT06706622·401 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amlenetug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amlenetug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amlenetug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lundbeck company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Lundbeck

Amlenetug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News